To this end, researchers further utilized an IFN-α mutant with stronger binding affinity with the receptor, namely anti-VEGFR2-IFNαmut, which significantly enhanced its antitumor activity and improved the tumor microenvironment by promoting immune cell activation [134]. The gene discussed is IFNA1; the disease is neoplasm.